Technology and Infrastructure

BAC’s CaptureSelect^® ligands offer a unique affinity purification solution based on Camelid-derived single domain antibody fragments. These small, 14 kD affinity ligands, are the platform solution for any biopharmaceutical purification challenge and have been proven for many applications to result in a higher yield and an increased purity of the biopharmaceutical, as well as a reduction in the number of purification steps which all affect the cost of goods of the biopharmaceutical. In addition, CaptureSelect ligands can be tailored to protect the biopharmaceutical by mild elution conditions. The manufacturing in yeast, without animal derived components, results in a high quality product without toxins and viruses.

The development of any CaptureSelect ligand is based on the flexibility and specificity of the mammalian immune system, enabling ligands to be designed for almost any target and selected to have specific affinity, specificity and elution profiles.

For further information on CaptureSelect technology visit our dedicated product and technology site www.captureselect.com.